AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms

NCT05198960 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1308

Enrollment

OTHER

Sponsor class

Conditions

Polycythemia Vera
Essential Thrombocythemia
Prefibrotic/Early Primary Myelofibrosis
JAK2 V617F
High-risk Patients

Interventions

DRUG: Direct Oral Anticoagulants
DRUG: Low-dose aspirin

Sponsor

University Hospital, Brest